Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
Tomonori Sato, Yoshihide Kawasaki, Masamitsu Maekawa, et al.
Metabolites (2020) Vol. 11, Iss. 1, pp. 1-1
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Yang Yang, Shuo Li, Yujiao Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 142
Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets
Nicola Antonio di Meo, Francesco Lasorsa, Monica Rutigliano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 14360-14360
Open Access | Times Cited: 111
Extracellular Vesicle-Mediated Transfer of LncRNA IGFL2-AS1 Confers Sunitinib Resistance in Renal Cell Carcinoma
Yihui Pan, Xuanxuan Lu, Guannan Shu, et al.
Cancer Research (2022) Vol. 83, Iss. 1, pp. 103-116
Open Access | Times Cited: 51
The Uniqueness of Clear Cell Renal Cell Carcinoma: Summary of the Process and Abnormality of Glucose Metabolism and Lipid Metabolism in ccRCC
Xiaochen Qi, Quanlin Li, Xiangyu Che, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 54
Current Insights into Potential Effects of Micro-Nanoplastics on Human Health by in-vitro Tests
Marta Llorca, Marinella Farré
Frontiers in Toxicology (2021) Vol. 3
Open Access | Times Cited: 53
DEPDC1 as a metabolic target regulates glycolysis in renal cell carcinoma through AKT/mTOR/HIF1α pathway
Sichen Di, Wenjin Chen, Wei Yang, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 7
Open Access | Times Cited: 6
Sex Differences in Molecular Mechanisms of Cardiovascular Aging
Vanessa Dela Justina, Jéssica Silva Miguez, Fernanda Priviero, et al.
Frontiers in Aging (2021) Vol. 2
Open Access | Times Cited: 27
Role of Metabolic Reprogramming of Long non-coding RNA in Clear Cell Renal Cell Carcinoma
Huijie Zhang, Lei Yu, Jing Chen, et al.
Journal of Cancer (2022) Vol. 13, Iss. 2, pp. 691-705
Open Access | Times Cited: 19
FADS1, a lipid metabolism-related diagnostic biomarker in KIRC
Tianmin Yang, Kai Sun, Fan Peng, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Enantioselective metabolomics by liquid chromatography-mass spectrometry
Carlos Calderón, Michael Lämmerhofer
Journal of Pharmaceutical and Biomedical Analysis (2021) Vol. 207, pp. 114430-114430
Closed Access | Times Cited: 26
Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma
Andrea Katharina Lindner, Gennadi Tulchiner, Andreas Seeber, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 18
Advances in Renal Cell Carcinoma Drug Resistance Models
Yien Xiang, Zheng Ge, Jianfeng Zhong, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 17
Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers
Filipa Amaro, Márcia Carvalho, Maria de Lourdes Bastos, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 3, pp. 295-295
Open Access | Times Cited: 14
Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics
Yunxia Wang, Xiaolin Liu, Luyao Gong, et al.
British Journal of Pharmacology (2023) Vol. 180, Iss. 23, pp. 2937-2955
Closed Access | Times Cited: 7
Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells
Magdalena Rausch, Adriano Rutz, Pierre‐Marie Allard, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 12, pp. 6467-6467
Open Access | Times Cited: 17
Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety
Filipa Amaro, Carolina Pisoeiro, Maria João Valente, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9898-9898
Open Access | Times Cited: 10
Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro
Susmita Ghosh, Mamatha Garige, P. Haggerty, et al.
Cell Cycle (2024) Vol. 23, Iss. 1, pp. 43-55
Open Access | Times Cited: 1
Elucidation and Regulation of Tyrosine Kinase Inhibitor Resistance in Renal Cell Carcinoma Cells from the Perspective of Glutamine Metabolism
K Morozumi, Yoshihide Kawasaki, Tomonori Sato, et al.
Metabolites (2024) Vol. 14, Iss. 3, pp. 170-170
Open Access | Times Cited: 1
Multi-omics and immunogenomics analysis revealed PFKFB3 as a targetable hallmark and mediates sunitinib resistance in papillary renal cell carcinoma: in silico study with laboratory verification
Zhongwen Lü, Yongsheng Pan, Songbo Wang, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 1
Decrease of Intracellular Glutamine by STF-62247 Results in the Accumulation of Lipid Droplets in von Hippel-Lindau Deficient Cells
Mathieu Johnson, Sarah Nowlan, Gülsüm Şahin, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 5
Multi-Omics Comparison of the Spontaneous Diabetes Mellitus and Diet-Induced Prediabetic Macaque Models
Zhu Yang, Dianqiang Yang, Fancheng Tan, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 7
Investigation of cystine as differential diagnostic biomarker between astrocytomas and oligodendrogliomas based on global- and targeted analysis using liquid chromatography/tandem mass spectrometric analysis
Masahiro Watanabe, Masamitsu Maekawa, Masayuki Kanamori, et al.
Advances in Biomarker Sciences and Technology (2023) Vol. 5, pp. 76-85
Open Access | Times Cited: 2
Safety and Efficacy of Glucagon-like Peptide 1 Receptor Agonists in Patients With Cirrhosis
Sean Michael Morris, Matthew J. Armstrong, Philip N. Newsome
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 6, pp. 1220-1222
Open Access | Times Cited: 5
Wide-Targeted Semi-Quantitative Analysis of Acidic Glycosphingolipids in Cell Lines and Urine to Develop Potential Screening Biomarkers for Renal Cell Carcinoma
Masamitsu Maekawa, Tomonori Sato, Chika Kanno, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 4098-4098
Open Access
Metabolomics Reveals Tyrosine Kinase Inhibitor Resistance-Associated Metabolic Events in Human Metastatic Renal Cancer Cells
Filipa Amaro, Márcia Carvalho, Maria de Lourdes Bastos, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6328-6328
Open Access
Page 1 - Next Page

Scroll to top